India Pesticides Ltd

- No current or future fundraising through debt or equity was mentioned in the transcript. - The company plans to fund its FY25 capex of Rs. 110 crores entirely through internal accruals. - Cash and cash equivalents at the end of Q1 FY25 stood at Rs. 140 crores, supporting a cash surplus status. - Management confirmed that India Pesticides Limited will remain a cash surplus company even after planned capex spending. - There is no indication of plans for issuing new debt or equity in the near future based on the discussion.

- India Pesticides Limited plans a capex of Rs. 110 crores for FY25, covering both the parent company (IPL) and its subsidiary Shalvis Specialties Limited (SSL) — Rs. 50 crores for IPL and Rs. 65 crores for SSL. - The capex will fund expansion including commissioning new formulation plant capacity (expected within the current or next month) and intermediate plants, enhancing backward integration. - New intermediate plants are being commissioned for backward integration of key fungicides previously imported. - Additional active ingredients (two molecules) are being developed and plants for them are expected to be commissioned by Q3 FY25. - Capex funding will be primarily from internal accruals; the company expects to remain cash surplus even after capex. - The Hamirpur technical plant is under construction and expected to be commissioned by Q3 FY25, contributing significantly to revenues next year. - Strategic focus includes enhancing R&D, backward integration, and expanding product and formulation capacities.

- India Pesticides expects sales growth of 15% to 20% for FY25 and similarly for FY26. - Volume growth is a key driver, with FY25 growth mostly volume-led; price increases are difficult but possible later in the year. - Q1 FY25 volume increased by 26% YoY, with a recovery seen especially in formulations. - Capacity expansions in formulation plants (30%-40% increase) will support sales growth. - Technical plant capacity currently at 66% utilization with plans to commission increased formulation capacity shortly. - Domestic market expected to grow 8% to 10% annually, bolstered by newly introduced domestic-oriented products. - Export volumes, previously declined due to channel inventory and adverse weather, are now picking up. - New molecules contributed about 18%-19% of revenue this quarter, indicating a growing product mix. - Overall, the company is confident in sustaining growth through capacity expansion, product mix improvement, and market recovery.

- EBITDA margin is expected to improve to around 18%-20% from Q3 FY25 onwards and remain in this range in FY26. - Sales growth guidance for FY25 and FY26 is 15%-20%, primarily volume-led with potential upside from price increases. - Domestic market sales expected to grow 8%-10% annually, supported by new product introductions. - Formulation capacity will be expanded by 30%-40% to support growth; technical plant capacity is sufficient. - New product contributions (including new molecules) are growing, with ~18%-19% revenue from new molecules in Q1 FY25. - Company aims to maintain a cash-surplus position and fund Rs. 110 crores capex internally in FY25. - Prices in international markets are stabilizing after a decline, with gradual recovery expected to support margin improvement. - Return to historic high EBITDA margins (above 25%) is unlikely in near term; margins above 20% possible with market recovery. - Overall, India Pesticides projects steady improvement in earnings and profitability driven by volume growth, capacity expansion, and gradual price recovery.

- As of Q1 FY25, India Pesticides has export orders worth approximately Rs. 100 crores pending. - In Q1 FY25, the company supplied export material worth Rs. 78 crores. - Export orders are gradually increasing, indicating pick-up in international market demand. - The company expects export volumes and prices to improve in coming quarters, with prices currently settling after a decline. - Domestic market demand remains strong, supported by a good Kharif sowing season.